HAVCR2 and melanoma: Sabatomimab blocks the binding of Tim-3 to PtdSer, while spartalizumab blocks the binding of PD-1 to PD-L1/2. A phase II clinical trial (NCT02608268) explored the dose expansion of sabatomimab combined with spartalizumab in patients with NSCLC and melanoma.